S&P 500 7,500.58 ▲ 80.48 (+1.08%) DOW 51,564.70 ▲ 72.15 (+0.14%) NASDAQ 26,517.93 ▲ 496.28 (+1.91%) US Markets Closed â€ĸ 03:49 AM ET

BYSI

BeyondSpring Inc.

Price Chart
Latest Quote

$1.61

+0.02 (+1.26%)
Current Price
Previous Close $1.59
Open $1.56
Day High $1.62
Day Low $1.56
Volume 32,257
Fetched: 2026-06-19T07:49:11
Stock Information
Shares Outstanding 41.12M
Total Debt $246K
Cash Equivalents $7.86M
Net Income $-8.18M
Sector Healthcare
Industry Biotechnology
Market Cap $66.20M
EPS (TTM) $-0.24
Exchange NCM
🌐 Visit Website
📊 Comprehensive Analysis
Company Data
Enterprise Value$62.31M
Income$-8.18M
Book/sh$-0.84
Cash/sh$0.19
Employees44
Financial Ratios
Quick Ratio0.64
Current Ratio1.09
Returns & Margins
ROA-19.29%
Ownership
Insider Ownership14.26%
Institutional Ownership14.55%
Insider & Institutional transactions data not available
Valuation Ratios
Forward P/E-3.43
P/B-1.92
Analyst Data
Recommendationnone
Technical Indicators
SMA20$1.65
SMA50$1.60
SMA200$1.71
RSI43.14
ATR0.0952
Shares Float31.95M
Short Float6.49%
Short Ratio93.00
Rel Volume1.48
Performance History
Week-2.42%
Month+24.81%
Quarter+3.21%
6 Months-18.69%
YTD+0.00%
Year-52.65%
3 Years+31.97%
5 Years-85.91%
10 Years-90.42%
Stock Score: ⭐ Premium
Based on debt, profitability, growth, and cash flow metrics
⭐ Premium Feature

Sign up for free to view detailed scoring breakdown — premium is free during our trial period!

Recent Price History
Date Close Volume
2026-06-18 $1.61 35,100
2026-06-17 $1.59 14,200
2026-06-16 $1.60 5,200
2026-06-15 $1.65 13,700
2026-06-12 $1.57 14,400
2026-06-11 $1.65 10,300
2026-06-10 $1.65 8,700
2026-06-09 $1.72 16,600
2026-06-08 $1.70 22,400
2026-06-05 $1.71 24,000
2026-06-04 $1.71 14,700
2026-06-03 $1.74 13,200
2026-06-02 $1.70 17,700
2026-06-01 $1.74 21,500
2026-05-29 $1.68 16,500
2026-05-28 $1.72 38,400
2026-05-27 $1.71 101,200
2026-05-26 $1.54 33,300
2026-05-22 $1.57 40,100
2026-05-21 $1.44 12,900
2026-05-20 $1.44 23,200
2026-05-19 $1.29 39,000
About BeyondSpring Inc.

BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform. The company's lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia (CIN). It also develops Plinabulin in combination with Plinabulin+docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy and radiation; nivolumab, a PD-1 antibody that has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer (ES-SCLC); in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small-molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

Period:
Loading...
Income Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Revenue
Total Revenue $0 $0 $0 $1,351,000
Operating Revenue $0 $0 $0 $1,351,000
Expenses
Total Expenses $8,945,000 $8,754,000 $15,081,000 $38,590,000
Other Income Expense $242,000 $-74,000 $836,000 $944,000
Other Non Operating Income Expenses $77,000 $22,000 $964,000 $1,373,000
Net Non Operating Interest Income Expense $78,000 $59,000 $322,000 $178,000
Operating Expense $8,945,000 $8,754,000 $15,081,000 $38,590,000
General And Administrative Expense $4,557,000 $6,110,000 $7,809,000 $13,008,000
Interest Expense - - $0 $17,000
Interest Expense Non Operating - - $0 $17,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest $4,496,000 $-3,295,000 $-13,093,000 $-33,279,000
Net Interest Income $78,000 $59,000 $322,000 $178,000
Interest Income $78,000 $59,000 $322,000 $195,000
Normalized Income $4,365,650 $-3,219,160 $-12,991,880 $-32,940,090
Net Income From Continuing And Discontinued Operation $-1,006,000 $-11,123,000 $-21,026,000 $-33,279,000
Total Operating Income As Reported $-8,945,000 $-8,754,000 $-15,081,000 $-37,239,000
Net Income Common Stockholders $-1,006,000 $-11,123,000 $-21,026,000 $-33,279,000
Net Income $-1,006,000 $-11,123,000 $-21,026,000 $-33,279,000
Net Income Including Noncontrolling Interests $-14,217,000 $-16,693,000 $-21,948,000 $-36,280,000
Net Income Discontinuous Operations $-5,502,000 $-7,828,000 $-7,933,000 -
Net Income Continuous Operations $-8,715,000 $-8,865,000 $-14,015,000 $-36,280,000
Pretax Income $-8,625,000 $-8,769,000 $-13,923,000 $-36,117,000
Interest Income Non Operating $78,000 $59,000 $322,000 $195,000
Operating Income $-8,945,000 $-8,754,000 $-15,081,000 $-37,239,000
Per Share
Diluted EPS $-0.02 $-0.28 $-0.54 $-0.85
Basic EPS $-0.02 $-0.28 $-0.54 $-0.85
Other
Tax Effect Of Unusual Items $34,650 $-20,160 $-26,880 $-90,090
Tax Rate For Calcs $0 $0 $0 $0
Normalized EBITDA (Bullshit earnings) $-9,023,000 $-8,373,000 $-14,651,000 $-35,439,000
Total Unusual Items $165,000 $-96,000 $-128,000 $-429,000
Total Unusual Items Excluding Goodwill $165,000 $-96,000 $-128,000 $-429,000
Reconciled Depreciation $87,000 $285,000 $302,000 $232,000
EBITDA (Bullshit earnings) $-8,858,000 $-8,469,000 $-14,779,000 $-35,868,000
EBIT $-8,945,000 $-8,754,000 $-15,081,000 $-36,100,000
Diluted Average Shares $40,406,347 $39,733,191 $38,996,463 $39,093,246
Basic Average Shares $40,406,347 $39,733,191 $38,996,463 $39,093,246
Diluted NI Availto Com Stockholders $-1,006,000 $-11,123,000 $-21,026,000 $-33,279,000
Minority Interests $13,211,000 $5,570,000 $922,000 $3,001,000
Tax Provision $90,000 $96,000 $92,000 $163,000
Gain On Sale Of Security $165,000 $-96,000 $-128,000 $-429,000
Research And Development $4,388,000 $2,644,000 $7,272,000 $25,582,000
Selling General And Administration $4,557,000 $6,110,000 $7,809,000 $13,008,000
Other Gand A $4,557,000 $6,110,000 $7,809,000 $13,008,000
Fetched: 2026-06-16
Balance Sheet (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Assets
Net Tangible Assets $-32,161,000 $-32,900,000 $-26,805,000 $-5,979,000
Total Assets $25,933,000 $34,315,000 $24,808,000 $46,222,000
Total Non Current Assets $5,051,000 $5,738,000 $6,389,000 $7,699,000
Other Non Current Assets $4,455,000 $4,873,000 $5,324,000 $339,000
Non Current Accounts Receivable $125,000 $113,000 $18,000 $8,000
Current Assets $20,882,000 $28,577,000 $18,419,000 $38,523,000
Other Current Assets $71,000 $68,000 $168,000 $763,000
Assets Held For Sale Current $8,023,000 $25,347,000 $2,622,000 -
Prepaid Assets $227,000 $240,000 $292,000 $492,000
Cash Cash Equivalents And Short Term Investments $12,561,000 $2,922,000 $5,396,000 $37,268,000
Cash And Cash Equivalents $7,786,000 $2,922,000 $5,396,000 $34,396,000
Restricted Cash - $0 $9,941,000 $0
Debt
Total Debt $320,000 $589,000 $847,000 $4,961,000
Long Term Debt And Capital Lease Obligation $0 $307,000 $589,000 $3,995,000
Current Debt And Capital Lease Obligation $320,000 $282,000 $258,000 $966,000
Current Debt - - - -
Other Current Borrowings - - - -
Liabilities
Total Liabilities Net Minority Interest $49,923,000 $48,600,000 $48,269,000 $49,229,000
Total Non Current Liabilities Net Minority Interest $36,347,000 $37,590,000 $40,311,000 $41,877,000
Liabilities Heldfor Sale Non Current $3,766,000 $6,197,000 $7,847,000 -
Tradeand Other Payables Non Current $3,891,000 $3,613,000 $3,593,000 $3,576,000
Non Current Deferred Liabilities $28,600,000 $27,400,000 $28,170,000 $34,221,000
Current Liabilities $13,576,000 $11,010,000 $7,958,000 $7,352,000
Other Current Liabilities $11,169,000 $8,980,000 $3,807,000 $122,000
Payables And Accrued Expenses $1,549,000 $1,136,000 $2,926,000 $3,583,000
Payables $611,000 $296,000 $579,000 $1,113,000
Total Tax Payable $248,000 $1,000 $18,000 $32,000
Accounts Payable $363,000 $295,000 $561,000 $1,081,000
Current Deferred Liabilities - - $1,751,000 $1,351,000
Income Tax Payable - - - $16,000
Other Non Current Liabilities - - - -
Equity
Common Stock Equity $-32,161,000 $-32,900,000 $-26,805,000 $-5,979,000
Total Equity Gross Minority Interest $-23,990,000 $-14,285,000 $-23,461,000 $-3,007,000
Stockholders Equity $-32,161,000 $-32,900,000 $-26,805,000 $-5,979,000
Gains Losses Not Affecting Retained Earnings $602,000 $1,336,000 $894,000 $436,000
Retained Earnings $-408,431,000 $-407,425,000 $-396,302,000 $-375,276,000
Other Equity Adjustments - - - $436,000
Preferred Securities Outside Stock Equity - - - -
Other
Ordinary Shares Number $41,122,320 $40,316,320 $39,029,163 $38,999,597
Share Issued $41,122,320 $40,316,320 $39,029,163 $38,999,597
Tangible Book Value $-32,161,000 $-32,900,000 $-26,805,000 $-5,979,000
Invested Capital $-32,161,000 $-32,900,000 $-26,805,000 $-5,979,000
Working Capital $7,306,000 $17,567,000 $10,461,000 $31,171,000
Capital Lease Obligations $320,000 $589,000 $847,000 $4,961,000
Total Capitalization $-32,161,000 $-32,900,000 $-26,805,000 $-5,979,000
Minority Interest $8,171,000 $18,615,000 $3,344,000 $2,972,000
Foreign Currency Translation Adjustments $602,000 $1,336,000 $894,000 $436,000
Additional Paid In Capital $375,664,000 $373,185,000 $368,599,000 $368,857,000
Capital Stock $4,000 $4,000 $4,000 $4,000
Common Stock $4,000 $4,000 $4,000 $4,000
Employee Benefits $90,000 $73,000 $112,000 $85,000
Non Current Deferred Revenue $28,600,000 $27,400,000 $28,170,000 $34,221,000
Long Term Capital Lease Obligation $0 $307,000 $589,000 $3,995,000
Current Capital Lease Obligation $320,000 $282,000 $258,000 $966,000
Pensionand Other Post Retirement Benefit Plans Current $538,000 $612,000 $967,000 $1,330,000
Current Accrued Expenses $938,000 $840,000 $2,347,000 $2,470,000
Net PPE $471,000 $752,000 $1,047,000 $7,352,000
Accumulated Depreciation $-641,000 $-554,000 $-482,000 $-551,000
Gross PPE $1,112,000 $1,306,000 $1,529,000 $7,903,000
Leases $271,000 $271,000 $272,000 $272,000
Other Properties $420,000 $624,000 $843,000 $6,983,000
Machinery Furniture Equipment $421,000 $411,000 $414,000 $648,000
Properties $0 $0 $0 $0
Other Short Term Investments $4,775,000 $0 $193,000 $2,872,000
Current Deferred Revenue - - $1,751,000 $1,351,000
Construction In Progress - - - $0
Fetched: 2026-06-16
Cash Flow Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Free Cash Flow
Free Cash Flow $-19,819,000 $-16,667,000 $-16,574,000 $-28,185,000
Operating Activities
Operating Cash Flow $-19,769,000 $-16,443,000 $-16,474,000 $-28,151,000
Cash Flow From Continuing Operating Activities $-19,769,000 $-16,443,000 $-16,474,000 $-28,151,000
Operating Gains Losses $-6,986,000 - $37,000 $-1,071,000
Investing Activities
Capital Expenditure $-50,000 $-224,000 $-100,000 $-34,000
Investing Cash Flow $10,787,000 $-12,012,000 $-100,000 $18,247,000
Cash Flow From Continuing Investing Activities $10,787,000 $-12,012,000 $-100,000 $18,247,000
Net Other Investing Changes - - - $-687,000
Financing Activities
Issuance Of Capital Stock $2,000,000 $3,000,000 $0 $0
Financing Cash Flow $4,968,000 $26,785,000 $4,000 $3,431,000
Cash Flow From Continuing Financing Activities $4,968,000 $26,785,000 $4,000 $3,431,000
Net Other Financing Charges $2,682,000 $19,874,000 - $5,000,000
Net Common Stock Issuance $2,000,000 $3,000,000 $0 $0
Common Stock Issuance $2,000,000 $3,000,000 $0 $0
Other
Issuance Of Debt $286,000 $3,911,000 $0 $0
Interest Paid Supplemental Data $0 $0 $0 $17,000
Income Tax Paid Supplemental Data $2,000 $7,000 $36,000 $367,000
End Cash Position $7,786,000 $2,922,000 $15,337,000 $34,396,000
Other Cash Adjustment Outside Changein Cash $-4,352,000 $-13,125,000 $-2,413,000 -
Beginning Cash Position $16,047,000 $17,750,000 $34,396,000 $41,625,000
Effect Of Exchange Rate Changes $105,000 $-33,000 $-76,000 $-756,000
Changes In Cash $-4,014,000 $-1,670,000 $-16,570,000 $-6,473,000
Net Issuance Payments Of Debt $286,000 $3,911,000 $0 $-1,569,000
Net Long Term Debt Issuance $286,000 $3,911,000 $0 $-1,569,000
Long Term Debt Issuance $286,000 $3,911,000 $0 $0
Net Investment Purchase And Sale $3,483,000 $-11,788,000 $0 $17,564,000
Sale Of Investment $18,432,000 $1,000,000 $1,300,000 $49,761,000
Purchase Of Investment $-14,949,000 $-12,788,000 $-1,300,000 $-32,197,000
Net Business Purchase And Sale $7,354,000 $0 - -
Sale Of Business $7,354,000 $0 - -
Net PPE Purchase And Sale $-50,000 $-224,000 $-100,000 $683,000
Purchase Of PPE $-50,000 $-224,000 $-100,000 $-34,000
Change In Working Capital $-122,000 $-2,989,000 $3,283,000 $6,409,000
Change In Other Working Capital $-2,001,000 $-1,001,000 $249,000 $-1,351,000
Change In Other Current Liabilities $-145,000 $-804,000 $-823,000 $-3,194,000
Change In Other Current Assets $212,000 $-181,000 $2,641,000 $11,583,000
Change In Payables And Accrued Expense $1,766,000 $-994,000 $437,000 $-1,963,000
Change In Accrued Expense $1,842,000 $-387,000 $111,000 $-1,388,000
Change In Payable $-76,000 $-607,000 $326,000 $-575,000
Change In Account Payable $-76,000 $-607,000 $326,000 $-575,000
Change In Prepaid Assets $46,000 $-9,000 $779,000 $1,334,000
Other Non Cash Items $747,000 $702,000 $1,086,000 $912,000
Stock Based Compensation $722,000 $2,255,000 $770,000 $1,666,000
Unrealized Gain Loss On Investment Securities $0 $-3,000 $-4,000 $-19,000
Depreciation Amortization Depletion $87,000 $285,000 $302,000 $232,000
Depreciation And Amortization $87,000 $285,000 $302,000 $232,000
Depreciation $87,000 $285,000 $302,000 $232,000
Gain Loss On Sale Of Business $-6,986,000 $0 - -
Net Income From Continuing Operations $-14,217,000 $-16,693,000 $-21,948,000 $-36,280,000
Proceeds From Stock Option Exercised - $0 $4,000 $0
Gain Loss On Sale Of PPE - $0 $37,000 $0
Repayment Of Debt - - $0 $-1,569,000
Long Term Debt Payments - - $0 $-1,569,000
Sale Of PPE - - $0 $717,000
Gain Loss On Investment Securities - - - $-1,071,000
Change In Receivables - - - -
Fetched: 2026-06-16